Starling Oncology, Inc. Capital Expenditures Incurred but Not yet Paid
Starling Oncology, Inc. (STLN) reported Capital Expenditures Incurred but Not yet Paid of $182.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Cash Flow
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-03-28
- Starling Oncology, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $182.00K.
- Starling Oncology, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|
| 2023-12-31 | $182.00K 10-K · filed 2024-03-28 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-28 |